Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection

Patel, 1969, Significance of the positive crossmatch test in kidney transplantation, N Engl J Med, 280, 735, 10.1056/NEJM196904032801401 Rodriguez, 2005, Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers, Am J Transplant, 5, 2778, 10.1111/j.1600-6143.2005.01074.x Mengel, 2005, Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial, Am J Transplant, 5, 1050, 10.1111/j.1600-6143.2005.00788.x Colvin, 2005, Antibody-mediated organ-allograft rejection, Nat Rev Immunol, 5, 807, 10.1038/nri1702 Haas, 2006, C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings, Am J Transplant, 6, 1829, 10.1111/j.1600-6143.2006.01356.x Casarez, 2007, Humoral rejection in pediatric orthotopic heart transplantation, J Heart Lung Transplant, 26, 114, 10.1016/j.healun.2006.11.011 Michaels, 2003, Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease, J Heart Lung Transplant, 22, 58, 10.1016/S1053-2498(02)00472-2 Mauiyyedi, 2001, Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries, J Am Soc Nephrol, 12, 574, 10.1681/ASN.V123574 David-Neto, 2007, C4d-positive chronic rejection: a frequent entity with a poor outcome, Transplantation, 84, 1391, 10.1097/01.tp.0000288807.52520.5e Feucht, 1991, Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection, Clin Exp Immunol, 86, 464, 10.1111/j.1365-2249.1991.tb02954.x Feucht, 1993, Capillary deposition of C4d complement fragment and early renal graft loss, Kidney Int, 43, 1333, 10.1038/ki.1993.187 Feucht, 1996, The humoral immune response towards HLA class II determinants in renal transplantation, Kidney Int, 50, 1464, 10.1038/ki.1996.460 Morgan, 1990 Ollert, 1994, Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps, J Immunol, 153, 2213, 10.4049/jimmunol.153.5.2213 Schweinle, 1989, Human mannose-binding protein activates the alternative complement pathway and enhances serum bactericidal activity on a mannose-rich isolate of Salmonella, J Clin Invest, 84, 1821, 10.1172/JCI114367 Matsushita, 1995, Cleavage of the third component of complement (C3) by mannose-binding protein-associated serine protease (MASP) with subsequent complement activation, Immunobiology, 194, 443, 10.1016/S0171-2985(11)80110-5 Murata, 2007, Synergistic deposition of C4d by complement-activating and non-activating antibodies in cardiac transplants, Am J Transplant, 7, 2605, 10.1111/j.1600-6143.2007.01971.x Perkins, 1991, Solution structure of human and mouse immunoglobulin M by synchrotron x-ray scattering and molecular graphics modelling. A possible mechanism for complement activation, J Mol Biol, 221, 1345, 10.1016/0022-2836(91)90937-2 McMullen, 2006, Mannose-binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo, Immunobiology, 211, 759, 10.1016/j.imbio.2006.06.011 Chan, 2006, The differing roles of the classical and mannose-binding lectin complement pathways in the events following skeletal muscle ischemia-reperfusion, J Immunol, 177, 8080, 10.4049/jimmunol.177.11.8080 Daha, 1989, Interaction of immunoglobulin A with complement and phagocytic cells, Prog Clin Biol Res, 297, 247 Rits, 1988, Activation of rat complement by soluble and insoluble rat IgA immune complexes, Eur J Immunol, 18, 1873, 10.1002/eji.1830181202 Lucisano Valim, 1991, The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions, Clin Exp Immunol, 84, 1, 10.1111/j.1365-2249.1991.tb08115.x Terai, 2006, Degalactosylated and/or denatured IgA, but not native IgA in any form, bind to mannose-binding lectin, J Immunol, 177, 1737, 10.4049/jimmunol.177.3.1737 Malhotra, 1995, Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein, Nat Med, 1, 237, 10.1038/nm0395-237 Ciurana, 2006, Competitive binding of pentraxins and IgM to newly exposed epitopes on late apoptotic cells, Cell Immunol, 239, 14, 10.1016/j.cellimm.2006.02.006 Nabata, 2008, C-reactive protein induces endothelial cell apoptosis and matrix metalloproteinase-9 production in human mononuclear cells: implications for the destabilization of atherosclerotic plaque, Atherosclerosis, 196, 129, 10.1016/j.atherosclerosis.2007.03.003 Korb, 1997, C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited, J Immunol, 158, 4525, 10.4049/jimmunol.158.10.4525 Navratil, 2001, The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells, J Immunol, 166, 3231, 10.4049/jimmunol.166.5.3231 Nauta, 2002, Direct binding of C1q to apoptotic cells and cell blebs induces complement activation, Eur J Immunol, 32, 1726, 10.1002/1521-4141(200206)32:6<1726::AID-IMMU1726>3.0.CO;2-R Racusen, 2003, Antibody-mediated rejection criteria—an addition to the Banff 97 classification of renal allograft rejection, Am J Transplant, 3, 708, 10.1034/j.1600-6143.2003.00072.x Mauiyyedi, 2002, Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification, J Am Soc Nephrol, 13, 779, 10.1681/ASN.V133779 Koo, 2004, C4d deposition in early renal allograft protocol biopsies, Transplantation, 78, 398, 10.1097/01.TP.0000128328.68106.54 Stewart, 2005, Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection, J Heart Lung Transplant, 24, 1710, 10.1016/j.healun.2005.03.019 Smith, 2005, C4d deposition in cardiac allografts correlates with alloantibody, J Heart Lung Transplant, 24, 1202, 10.1016/j.healun.2004.07.021 Magro, 2002, Humorally mediated posttransplantation septal capillary injury syndrome as a common form of pulmonary allograft rejection: a hypothesis, Transplantation, 74, 1273, 10.1097/00007890-200211150-00013 Magro, 2003, Evidence that humoral allograft rejection in lung transplant patients is not histocompatibility antigen-related, Am J Transplant, 3, 1264, 10.1046/j.1600-6143.2003.00229.x Feucht, 2003, Complement C4d in graft capillaries—the missing link in the recognition of humoral alloreactivity, Am J Transplant, 3, 646, 10.1034/j.1600-6143.2003.00171.x Fishbein, 2004, Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy, Curr Opin Cardiol, 19, 166, 10.1097/00001573-200403000-00018 Ionescu, 2005, C4d deposition in lung allografts is associated with circulating anti-HLA alloantibody, Transpl Immunol, 15, 63, 10.1016/j.trim.2005.05.001 Miller, 2004, Acute humoral rejection of human lung allografts and elevation of C4d in bronchoalveolar lavage fluid, Am J Transplant, 4, 1323, 10.1111/j.1600-6143.2004.00508.x Wallace, 2005, C4d staining of pulmonary allograft biopsies: an immunoperoxidase study, J Heart Lung Transplant, 24, 1565, 10.1016/j.healun.2004.11.038 Stewart, 2007, Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection, J Heart Lung Transplant, 26, 1229, 10.1016/j.healun.2007.10.017 Wasowska, 2001, Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice, Transplantation, 71, 727, 10.1097/00007890-200103270-00007 Nakashima, 2002, Membrane attack complex contributes to destruction of vascular integrity in acute lung allograft rejection, J Immunol, 169, 4620, 10.4049/jimmunol.169.8.4620 Morgan, 1999 Bohmig, 2002, Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury, J Am Soc Nephrol, 13, 1091, 10.1681/ASN.V1341091 Wahrmann, 2003, Flow cytometry based detection of HLA alloantibody mediated classical complement activation, J Immunol Methods, 275, 149, 10.1016/S0022-1759(03)00012-7 Bannett, 1987, Experiences with known ABO-mismatched renal transplants, Transplant Proc, 19, 4543 Bannett, 1989, ABO incompatible renal transplantation: a qualitative analysis of native endothelial tissue ABO antigens after transplantation, Transplant Proc, 21, 783 Racusen, 2006, Antibody-mediated rejection in renal allografts: lessons from pathology, Clin J Am Soc Nephrol, 1, 415, 10.2215/CJN.01881105 Snyderman, 1975, Quantification of mouse macrophage chemotaxis in vitro: role of C5 for the production of chemotactic activity, Infect Immun, 11, 488, 10.1128/IAI.11.3.488-492.1975 Gerard, 1989, Characterization of a receptor for C5a anaphylatoxin on human eosinophils, J Biol Chem, 264, 1760, 10.1016/S0021-9258(18)94252-3 Gerard, 1991, The chemotactic receptor for human C5a anaphylatoxin, Nature, 349, 614, 10.1038/349614a0 Okinaga, 2003, C5L2, a nonsignaling C5A binding protein, Biochemistry, 42, 9406, 10.1021/bi034489v Chen, 2007, C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a, Nature, 446, 203, 10.1038/nature05559 Becker, 1972, The relationship of the chemotactic behavior of the complement-derived factors, C3a, C5a, and C567, and a bacterial chemotactic factor to their ability to activate the proesterase 1 of rabbit polymorphonuclear leukocytes, J Exp Med, 135, 376, 10.1084/jem.135.2.376 Snyderman, 1970, Polymorphonuclear leukocyte chemotactic activity in rabbit serum and guinea pig serum treated with immune complexes: evidence for C5a as the major chemotactic factor, Infect Immun, 1, 521, 10.1128/IAI.1.6.521-525.1970 Marder, 1985, Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg, J Immunol, 134, 3325, 10.4049/jimmunol.134.5.3325 Hirayama, 2006, Prevention of neutrophil migration ameliorates rat lung allograft rejection, Mol Med (Cambridge, Mass), 12, 208, 10.2119/2006-00036.Hirayama DiGiovine, 1996, Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8, J Immunol, 157, 4194, 10.4049/jimmunol.157.9.4194 Hirsch, 1999, Bronchiolitis obliterans syndrome after (heart-)lung transplantation. Impaired antiprotease defense and increased oxidant activity, Am J Respir Crit Care Med, 160, 1640, 10.1164/ajrccm.160.5.9902012 Fahim, 2007, The cellular lesion of humoral rejection: predominant recruitment of monocytes to peritubular and glomerular capillaries, Am J Transplant, 7, 385, 10.1111/j.1600-6143.2006.01634.x Mollnes, 2002, Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation, Blood, 100, 1869 Goldstein, 1974, Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes, J Immunol, 113, 1583, 10.4049/jimmunol.113.5.1583 Sacks, 1978, Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage, J Clin Invest, 61, 1161, 10.1172/JCI109031 Riedemann, 2002, Expression and function of the C5a receptor in rat alveolar epithelial cells, J Immunol, 168, 1919, 10.4049/jimmunol.168.4.1919 Guo, 2002, Altered neutrophil trafficking during sepsis, J Immunol, 169, 307, 10.4049/jimmunol.169.1.307 Laudes, 2002, Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis, Am J Pathol, 160, 1867, 10.1016/S0002-9440(10)61133-9 Laudes, 2002, Expression and function of C5a receptor in mouse microvascular endothelial cells, J Immunol, 169, 5962, 10.4049/jimmunol.169.10.5962 Molad, 1994, Immunocomplexes stimulate different signalling events to chemoattractants in the neutrophil and regulate L-selectin and beta 2-integrin expression differently, Biochem J, 299, 881, 10.1042/bj2990881 Jagels, 2000, C3a and C5a enhance granulocyte adhesion to endothelial and epithelial cell monolayers: epithelial and endothelial priming is required for C3a-induced eosinophil adhesion, Immunopharmacology, 46, 209, 10.1016/S0162-3109(99)00178-2 Albrecht, 2004, C5a-induced gene expression in human umbilical vein endothelial cells, Am J Pathol, 164, 849, 10.1016/S0002-9440(10)63173-2 Monsinjon, 2003, Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells, FASEB J, 17, 1003, 10.1096/fj.02-0737com Hillmen, 2006, The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria, N Engl J Med, 355, 1233, 10.1056/NEJMoa061648 Fitch, 1999, Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass, Circulation, 100, 2499, 10.1161/01.CIR.100.25.2499 Verrier, 2004, Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial, JAMA, 291, 2319, 10.1001/jama.291.19.2319 Shernan, 2004, Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass, Ann Thorac Surg, 77, 942, 10.1016/j.athoracsur.2003.08.054 Armstrong, 2007, Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial, JAMA, 297, 43, 10.1001/jama.297.1.43 Granger, 2003, Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial, Circulation, 108, 1184, 10.1161/01.CIR.0000087447.12918.85 Mahaffey, 2003, Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial, Circulation, 108, 1176, 10.1161/01.CIR.0000087404.53661.F8 Wang, 2005, Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine, Transplantation, 79, 1121, 10.1097/01.TP.0000161218.58276.9A Wang, 2007, Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation, J Immunol, 179, 4451, 10.4049/jimmunol.179.7.4451 Sengelov, 1994, Secretory vesicles are the intracellular reservoir of complement receptor 1 in human neutrophils, J Immunol, 153, 804, 10.4049/jimmunol.153.2.804 Xia, 1999, The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells, J Immunol, 162, 2281, 10.4049/jimmunol.162.4.2281 Helmy, 2006, CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens, Cell, 124, 915, 10.1016/j.cell.2005.12.039 Rogers, 1993, Neutrophils are involved in acute, nonspecific resistance to Listeria monocytogenes in mice, Infect Immun, 61, 5090, 10.1128/IAI.61.12.5090-5096.1993 Gregory, 2002, Complementary adhesion molecules promote neutrophil-Kupffer cell interaction and the elimination of bacteria taken up by the liver, J Immunol, 168, 308, 10.4049/jimmunol.168.1.308 Conlan, 1994, Neutrophils are essential for early anti-Listeria defense in the liver, but not in the spleen or peritoneal cavity, as revealed by a granulocyte-depleting monoclonal antibody, J Exp Med, 179, 259, 10.1084/jem.179.1.259 Langnaese, 2000, Cloning of Z39Ig, a novel gene with immunoglobulin-like domains located on human chromosome X, Biochim Biophys Acta, 1492, 522, 10.1016/S0167-4781(00)00131-7 Vogt, 2006, VSIG4, a B7 family-related protein, is a negative regulator of T cell activation, J Clin Invest, 116, 2817, 10.1172/JCI25673 Lee, 2006, Z39Ig is expressed on macrophages and may mediate inflammatory reactions in arthritis and atherosclerosis, J Leukoc Biol, 80, 922, 10.1189/jlb.0306160 Wiesmann, 2006, Structure of C3b in complex with CRIg gives insights into regulation of complement activation, Nature, 444, 217, 10.1038/nature05263 Nicod, 2005, Upregulation of CD40, CD80, CD83 or CD86 on alveolar macrophages after lung transplantation, J Heart Lung Transplant, 24, 1067, 10.1016/j.healun.2004.07.011 Frachon, 1994, Emergence of inflammatory alveolar macrophages during rejection or infection after lung transplantation, Transplantation, 57, 1621, 10.1097/00007890-199457110-00015 Lee, 2007, The involvement of FcR mechanisms in antibody-mediated rejection, Transplantation, 84, 1324, 10.1097/01.tp.0000287457.54761.53 El-Sawy, 2005, Inhibition of polymorphonuclear leukocyte-mediated graft damage synergizes with short-term costimulatory blockade to prevent cardiac allograft rejection, Circulation, 112, 320, 10.1161/CIRCULATIONAHA.104.516708 Ashtekar, 2003, Poly's plea: membership to the club of APCs, Trends Immunol, 24, 485, 10.1016/S1471-4906(03)00235-7 Carney, 1986, Elimination of terminal complement complexes in the plasma membrane of nucleated cells: influence of extracellular Ca2+ and association with cellular Ca2+, J Immunol, 137, 263, 10.4049/jimmunol.137.1.263 Cybulsky, 1990, Cytosolic calcium and protein kinase C reduce complement-mediated glomerular epithelial injury, Kidney Int, 38, 803, 10.1038/ki.1990.274 Kraus, 2000, Cell desensitization by sublytic C5b-9 complexes and calcium ionophores depends on activation of protein kinase C, Eur J Immunol, 30, 1272, 10.1002/(SICI)1521-4141(200005)30:5<1272::AID-IMMU1272>3.0.CO;2-9 Foreman, 1994, C5a-induced expression of P-selectin in endothelial cells, J Clin Invest, 94, 1147, 10.1172/JCI117430 Saadi, 1995, Transient perturbation of endothelial integrity induced by natural antibodies and complement, J Exp Med, 181, 21, 10.1084/jem.181.1.21 Saadi, 1995, Complement-mediated regulation of tissue factor activity in endothelium, J Exp Med, 182, 1807, 10.1084/jem.182.6.1807 Bustos, 1997, Modulation of eicosanoid metabolism in endothelial cells in a xenograft model. Role of cyclooxygenase-2, J Clin Invest, 100, 1150, 10.1172/JCI119626 Kilgore, 1996, The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells, Am J Pathol, 149, 953 Hattori, 1989, Complement proteins C5b-C9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface, J Biol Chem, 264, 9053, 10.1016/S0021-9258(18)81901-9 Qian, 1998, C6 produced by macrophages contributes to cardiac allograft rejection, Transplantation, 65, S77, 10.1097/00007890-199806270-00319 Ota, 2005, Terminal complement components mediate release of von Willebrand factor and adhesion of platelets in arteries of allografts, Transplantation, 79, 276, 10.1097/01.TP.0000146195.76904.D3 Halloran, 1990, The significance of the anti-class I antibody response: I. Clinical and pathological features of anti-class I-mediated rejection, Transplantation, 49, 85, 10.1097/00007890-199001000-00019 Meehan, 2003, Platelets and capillary injury in acute humoral rejection of renal allografts, Hum Pathol, 34, 533, 10.1016/S0046-8177(03)00189-8 Polley, 1983, Human platelet activation by C3a and C3a des-arg, J Exp Med, 158, 603, 10.1084/jem.158.2.603 Sims, 1988, Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity, J Biol Chem, 263, 18205, 10.1016/S0021-9258(19)81346-7 Dole, 2005, Activated platelets induce Weibel-Palade-body secretion and leukocyte rolling in vivo: role of P-selectin, Blood, 106, 2334, 10.1182/blood-2005-04-1530 Padilla, 2004, P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface, Blood, 103, 2150, 10.1182/blood-2003-08-2956 von Hundelshausen, 2001, RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium, Circulation, 103, 1772, 10.1161/01.CIR.103.13.1772 Weiss, 1979, Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in alpha-granules, platelet factor 4, beta-thromboglobulin, and platelet-derived growth factor, Blood, 54, 1296, 10.1182/blood.V54.6.1296.1296 Ekdahl, 1999, Alterations in C3 activation and binding caused by phosphorylation by a casein kinase released from activated human platelets, J Immunol, 162, 7426, 10.4049/jimmunol.162.12.7426 Nilsson-Ekdahl, 2001, Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1, Eur J Immunol, 31, 1047, 10.1002/1521-4141(200104)31:4<1047::AID-IMMU1047>3.0.CO;2-Y Del Conde, 2005, Platelet activation leads to activation and propagation of the complement system, J Exp Med, 201, 871, 10.1084/jem.20041497 Coppinger, 2004, Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions, Blood, 103, 2096, 10.1182/blood-2003-08-2804 Morrell, 2008, In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody, Circ Res, 10.1161/CIRCRESAHA.107.170332 Melchers, 1985, Growth control of activated, synchronized murine B cells by the C3d fragment of human complement, Nature, 317, 264, 10.1038/317264a0 Matsumoto, 1991, Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement recepor, J Exp Med, 173, 55, 10.1084/jem.173.1.55 Bradbury, 1992, The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules, J Immunol, 149, 2841, 10.4049/jimmunol.149.9.2841 Dempsey, 1996, C3d of complement as a molecular adjuvant: bridging innate and acquired immunity, Science, 271, 348, 10.1126/science.271.5247.348 Molina, 1996, Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2, Proc Natl Acad Sci U S A, 93, 3357, 10.1073/pnas.93.8.3357 Marsh, 2001, The allogeneic T and B cell response is strongly dependent on complement components C3 and C4, Transplantation, 72, 1310, 10.1097/00007890-200110150-00022 Desvaux, 2004, Acute renal allograft rejections with major interstitial oedema and plasma cell-rich infiltrates: high gamma-interferon expression and poor clinical outcome, Nephrol Dial Transplant, 19, 933, 10.1093/ndt/gfh027 Pratt, 2002, Local synthesis of complement component C3 regulates acute renal transplant rejection, Nat Med, 8, 582, 10.1038/nm0602-582 Peng, 2006, Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype, J Immunol, 176, 3330, 10.4049/jimmunol.176.6.3330 Heeger, 2005, Decay-accelerating factor modulates induction of T cell immunity, J Exp Med, 201, 1523, 10.1084/jem.20041967 Lalli, 2007, Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production, J Immunol, 179, 5793, 10.4049/jimmunol.179.9.5793